Abstract: Parkinson's disease (PD) is a progressive neurodegenerative disorder second only to Alzheimer's disease. Diagnosis remains clinical, based on phenotypic patterns. In the last decade many attempts to develop early differential pre-clinical markers have been reported. In this presentation, the molecular risk factors that may link between the etiopathogenesis leading to PD and peripheral markers will be discussed. Genetic variation known to be involved in familial forms of PD will be shown to be linked to sporadic cases, as for example leucine-rich repeat kinase 2 (LRRK2) that was found to regulate microRNA-mediated translation regulation. In addition postmortem microarray findings of transcription alterations will be compared to the peripheral findings of mRNA profiles. Molecular processes involved in ubiquitination and proteasome, autophagy, mitochondrial dysfunction and the nicotinic and adenosine A2 protection will be discussed. The question of what time-point should be used measuring the different markers and the course of the disease considered, and the future possibilities in exploring these techniques will be debated. the etiopathogenesis leading to PD and peripheral markers will be discussed.
Introduction
Parkinson's disease (PD) is a progressive neurodegenerative disorder second only to Alzheimer's disease. Since the fact that diagnosis remains clinical based on the presence of a combination of cardinal signs, including rest tremor, bradykinesia, rigidity, and loss of postural reflexes, the diagnosis will most often be made after more than 70-80% of the dopaminergic neurons have degenerated [1] . There is wide agreement that a preclinical approach detecting at-risk PD subjects would enable earlier preventive therapy that might slow down or even stop the neurodegeneration.
In this review the molecular risk factors will be described, beginning with familial genetic findings and continuing with transcription profile studies in the central nervous system (CNS)that have been studied postmortem to the new findings of transcription factors, alterations found in peripheral blood samples, which link some again to familial genetic forms.
Since the discovery of the first disease-causing mutation in the -synuclein gene (SNCA/ PARK1/4), a number of genes and loci have been implicated in PD denoted as PARK1 to 14. Those genes harboring mutations that cause late-onset dominantly inherited PD include SNCA and leucine-rich repeat kinase 2 (LRRK2/PARK8), whereas early-onset recessive parkinsonism is associated with homozygous and compound heterozygous mutations in parkin (PRKN/PARK2), Pten-induced kinase 1 (PINK1/PARK6) and Oncogene DJ-1 (DJ-1/PARK7) [2] . Despite their importance in identifying key molecules in the pathogenesis of PD, these genetic mutations remain relatively rare (less than 5%). On the other hand, association studies in sporadic PD have found that similar genes such as SNCA polymorphism, as well as microtubuleassociated protein tau/saitohin (MAPT/STH), glucoberebrosidase (GBA) and LRRK2 are associated with the risk of PD, but as the highest odds ratio after meta-analysis reaches 3.4 it must still be validated in larger and diverse population [3] .
As an additional approach to finding new candidate molecules involved in the etiopathogenesis of PD, many gene expression studies have been conducted on postmortem brain tissue, especially on the substantia nigra (SN), the affected brain region (for review see Table 1 ).
Studying the various reports and different brain regions reveals the involvement of protein metabolism and handling (e.g. aggregation and ubiquitination processes, proteasome and vesicular trafficking), the energy pathway including the mitochondria, the response to stress (e.g. heat shock proteins and their chaperones), the autophagy processes, inflammation, adenosine receptors (caffeine) as well as oxidative metabolism (Table 1 ). In addition, in many of the postmortem studies found a link between familial to sporadic PD, with the finding of alterations in the transcription of SNCA [6, 8, 9, 12] , which may point to a common neurodegeneration mechanism in both cases. Similarly, UCHL-1 (PARK5) and DJ-1 (PARK7) mRNA were found to alter in sporadic PD [4] [5] [6] 10] .
As the availability of postmortem brain tissue is limited, as well as the need for early diagnosis research has been directed to the periphery, with the aim of finding similar alterations there as in the CNS. Indeed, such alterations have been confirmed [6] . As in the postmortem brain studies, many of the molecular pathways discovered in the first approach have also been found in the periphery (Table 1) . TRIM24 mRNA was found to alter its expression in peripheral blood both in sporadic PD as well as in carriers of the PARK2 or LRRK2 mutations [19] . TRIM24 is involved in the transcription control of some nuclear receptors, but was also found to be involved in the control of apoptosis and autophagia mechanisms. Therefore it could be hypothesized that this marker may point to the common mechanism involving autophagy and oxidative stress leading to apoptosis. In PD carriers of the LRRK2 mutation gene expression profiles in blood samples revealed the involvement of the
ubiquitin-proteasome system [18] . Again, also in this study one can conclude similar molecular pathways of the protein metabolism to be involved both in sporadic and familial PD. In a familial PD study with duplications of the SNCA gene it was shown that this duplication directly influences the expression of the SNCA mRNA in blood [18] . This finding enhances the notion of the involvement of SNCA in the etiopathology of PD.
From the current findings, it could be concluded that peripheral molecular markers can mirror the disease processes and may be even detect progression of the disease. Of course, the path is still long, in order to reach the best set of markers that will best provide early differential diagnosis for PD. But such future perspectives seem to be nearing. For such an aim, there is a need for a longitudinal large scale international study, in which at-risk subjects will be followed up for their progression to PD phenotypes while in parallel different markers will be collected, as for example [18] Annotation: A 2A AR, adenosine 2A receptor; ALAS2, 5-aminolevulinate synthase 2; ALDH1A1, aldehyde dehydrogenase 1 family member A1; ANP32B, acidic (leucine-rich) nuclear phosphoprotein
